Market Overview

Invicro Names Dr. Brian Avants as Senior Director of Machine Learning


Invicro LLC, a Konica Minolta company and a leading provider of imaging
services and software for research and drug development, today announced
the appointment of Brian Avants, Ph.D. as Senior Director of Machine

This press release features multimedia. View the full release here:

Invicro Names Dr. Brian Avants as Senior Director of Machine Learning (Photo: Business Wire)

Invicro Names Dr. Brian Avants as Senior Director of Machine Learning (Photo: Business Wire)

Backed by more than 20 years of biomedical data analytics expertise, Dr.
Avants will lead the strategic efforts to expand Invicro's machine
learning (ML) and artificial intelligence (AI) capabilities. As an
interdisciplinary scientist with a focus on neuro MR, Dr. Avants has
broadly explored the synergies between machine learning, brain mapping
and mathematical modeling. Dr. Avants will utilize this expertise in
developing computational and algorithmic advances to enhance Invicro's
imaging and data analytics platform. Within a single platform, Pharma
and biotech customers will value a robust solution that combines leading
data management and domain knowledge modeling methods with
state-of-the-art ML and AI tools, bolstering Invicro's analysis
solutions in oncology, neuro, pulmonary, and other therapeutic areas.
Dr. Avants will be an integral contributor to the Konica Minolta's
global AI team, to ensure there is ongoing collaboration and alignment
with Invicro.

"Invicro is fortunate to have someone with Brian's high-caliber of
analysis experience and knowledge to join the team," stated Jacob
Hesterman, Ph.D., Founding Partner and Head of R&D at Invicro.
"Combining Brian's MR and machine learning expertise with our industry
leading PET analysis capabilities, uniquely positions Invicro as the
global premier service provider of PET and MR analysis for imaging

Most recently, Dr. Avants was the Associate Director, Translational and
Advanced Analytics at Biogen, where he worked on multiple modality
longitudinal brain mapping for Alzheimer's disease and related
disorders. Prior to Biogen, Dr. Avants was an Assistant Professor of
Radiology at the University of Pennsylvania.

"I'm excited to join the dynamic team at Invicro," said Dr. Avants.
"This opportunity allows me to leverage my passion for neuro mapping and
machine learning that will provide our customers an advanced platform
with revolutionary technologies and innovative AI solutions."

Dr. Avants holds a B.A. in Physics from New College of Florida, a M.S.
in Computer Science and a Ph.D. in Bioengineering both from the
University of Pennsylvania. Dr. Avants has been consistently recognized
and honored for his research, publications and overall contributions to
biomedical image quantification and open science. He is lead developer
of Advanced Normalization Tools (ANTs), ANTsR and ANTsPy which,
together, form a state-of-the-art framework for integrative analysis and
interpretation of imaging and related data.

About Invicro
Headquarter in Boston, MA, Invicro was founded
in 2008 with the mission of improving the role and function of imaging
in translational drug discovery and development across all therapeutic
areas. Invicro's multi-disciplinary team provides a full range of image
informatics, engineering and operational services. Originally focused on
imaging in discovery phase, in 2016 Invicro expanded its offering in
clinical phase research with the acquisition of Molecular Neuroimaging,
LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.
Now as part of the Konica Minolta precision medicine organization and
with their sister company Ambry Genetics, Invicro develops and leverages
the latest approaches in quantitative biomarkers including imaging,
quantitative pathology and genomics. The successful integration of the
discovery and clinical teams onto Invicro's industry-leading software
informatics platforms, VivoQuant® and iPACS®, has inspired a strong and
growing presence in the pre-clinical to late-phase clinical markets. For
more information, visit

About Konica Minolta
Konica Minolta, Inc. (Konica Minolta)
is a global digital technology company with core strengths in imaging
and data analysis, optics, materials, and nano-fabrication. Through
innovation, Konica Minolta creates products and digital solutions for
the betterment of business and society—today and for generations to
come. Across its Business Technologies, Healthcare, and
Industrial-facing businesses, the company aspires to be an Integral
Value Provider that applies the full range of its expertise to offer
comprehensive solutions to the customer's most pressing problems, works
with the partners to ensure the solutions are sustainable, anticipates
and addresses tomorrow's issues, and tailors each solution to meet the
unique and specific needs of its valued customers. Leveraging these
capabilities, Konica Minolta contributes to productivity improvement and
workflow change for its customers, and provides leading-edge service
solutions in the IoT era. Headquartered in Tokyo and with operations in
more than 50 countries, Konica Minolta has more than 43,000 employees
serving approximately two million customers in over 150 countries.
Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For
further information, visit:

View Comments and Join the Discussion!